BETHLEHEM, Pa., March 12, 2012 /PRNewswire/ --Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today it has entered into a distribution agreement with INyDIA Labs, based in Madrid, Spain, for My5-FU, a test that measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients.

"Our collaboration with INyDIA will allow us to provide cancer patients in Spain and Portugal more personalized treatment," said Adrienne Choma, Esq., Sr. VP and chief marketing officer of Saladax. "With this agreement, we expand availability of Saladax's My5-FU diagnostic assay in the global market."

INyDIA will be the exclusive provider of My5-FU test kits to laboratories in Spain and Portugal, enabling oncologists to individualize 5-FU dosing to optimize therapeutic efficacy and reduce toxicity for their patients.INyDIA, which specializes in producing in vitro diagnostic reagents and instrumentation, including array readers and liquid handling platforms, also offers its customers other manufacturers' products focused in personalized medicine.

"We're pleased to offer Saladax's unique technology to oncologists in Spain and Portugal to ensure personalized care is provided to their patient populations," said Santiago R. Maceira, country manager for INyDIA.

About My5-FUSaladax's first commercially available test for innovative dose management; My5-FU measures levels of 5-fluorouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.

About Saladax Biomedical, Inc.Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company's 15 MyCare dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold in the European Union by Saladax and its distribution partners as a CE-marked product and will be distributed in Japan by FALCO biosystems. In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose through a license to Saladax proprietary technology. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds. For more information, visit http://www.saladax.com.

My5-FU is a registered trademark of Saladax Biomedical, Inc. OnDose is a registered trademark of Myriad Genetics, Inc.

Saladax Biomedical, Inc. Adrienne Choma, Esq. Sr. VP & Chief Marketing Officer achoma@saladax.com

Media Contact:Tiberend Strategic Advisors, Inc.212-827-0020 Andrew Mielach amielach@tiberend.com or Jason Rando jrando@tiberend.com

Read more from the original source:
Saladax Biomedical, Inc. Expands Distribution of My5-FU in Spain and Portugal

Comments are closed.